Failing the Public Health — Rofecoxib, Merck, and the FDA
Failing the Public Health — Rofecoxib, Merck, and the FDA
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
On May 21, 1999, Merck was granted approval by the Food and Drug Administration (FDA) to market rofecoxib (Vioxx). On September 30, 2004, after more than 80 million patients had taken this medicine and annual sales had topped $2.5 billion, the company withdrew the drug because of an excess risk of myocardial infarctions and strokes. This represents...
Alternative Titles
Full title
Failing the Public Health — Rofecoxib, Merck, and the FDA
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_223937474
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_223937474
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMp048286
